|Values are valid only on day of printing.|
Effective January 1, 2013
The American Medical Association’s (AMA) new molecular CPT codes took effect on January 1, 2013 for purposes of Medicare reimbursement claims. Based on the new codes, the Mayo Medical Laboratories (MML) test catalog has been updated to reflect the coding suggestions for the impacted molecular tests.
All coding and billing changes associated with the new codes are reflected in the Client Price Portal.
The new codes impact MML clients in two ways:
Effective July 1, 2013
The new AMA set of Tier 2 Molecular Pathology CPT codes take effect on July 1, 2013. These CPT codes are gene-specific and provide updates to testing previously coded with the unlisted CPT, 81479.
Palmetto GBA, a third-party administrator of Medicare that processes all claims for California, Nevada, and Hawaii, a McKesson Z-Code or a Palmetto Test Indicator (PTI) code to identify molecular diagnostic tests and to determine coverage and reimbursement. MML has applied for and been granted by Palmetto the attached list of PTI codes for use on our molecular diagnostic tests.